Current landscape of cystic fibrosis gene therapy

被引:0
|
作者
Plasschaert, Lindsey W. [1 ]
MacDonald, Kelvin D. [2 ,3 ]
Moffit, Jeffrey S. [2 ]
机构
[1] Plasschaert Consulting, Cambridge, MA USA
[2] Carbon Biosci, Waltham, MA 95648 USA
[3] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA
关键词
cystic fibrosis; CFTR; gene therapy; viral vector; airway; transduction; TRANSMEMBRANE CONDUCTANCE REGULATOR; STRUCTURAL LUNG-DISEASE; ADENOASSOCIATED VIRUS; IN-VITRO; AEROSOL DELIVERY; CLEARANCE INDEX; DOUBLE-BLIND; AAV-CFTR; R-DOMAIN; PHASE-I;
D O I
10.3389/fphar.2024.1476331
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cystic fibrosis is a life-threatening disease that is caused by mutations in CFTR, a gene which encodes an ion channel that supports proper function of several epithelial tissues, most critically the lung. Without CFTR, airway barrier mechanisms are impaired, allowing for chronic, recurrent infections that result in airway remodeling and deterioration of lung structure and function. Small molecule modulators can rescue existing, defective CFTR protein; however, they still leave a subset of people with CF with no current disease modifying treatments, aside from lung transplantation. Gene therapy directed to the lung is a promising strategy to modify CF disease in the organ most associated with morbidity and mortality. It is accomplished through delivery of a CFTR transgene with an airway permissive vector. Despite more than three decades of research in this area, a lung directed gene therapy has yet to be realized. There is hope that with improved delivery vectors, sufficient transduction of airway cells can achieve therapeutic levels of functional CFTR. In order to do this, preclinical programs need to meet a certain level of CFTR protein expression in vitro and in vivo through improved transduction, particularly in relevant airway cell types. Furthermore, clinical programs must be designed with sensitive methods to detect CFTR expression and function as well as methods to measure meaningful endpoints for lung structure, function and disease. Here, we discuss the current understanding of how much and where CFTR needs to be expressed, the most advanced vectors for CFTR delivery and clinical considerations for detecting CFTR protein and function in different patient subsets.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Advances in cystic fibrosis gene therapy
    Griesenbach, U
    Geddes, DM
    Alton, EWFW
    CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (06) : 542 - 546
  • [32] Update on gene therapy for cystic fibrosis
    Griesenbach, U
    Geddes, DM
    Alton, EWFW
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2003, 5 (05) : 489 - 494
  • [33] Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways
    Cmielewski, Patricia
    Farrow, Nigel
    Devereux, Sharnna
    Parsons, David
    Donnelley, Martin
    EXPERIMENTAL LUNG RESEARCH, 2017, 43 (9-10) : 426 - 433
  • [34] Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic
    Donnelley, Martin
    Parsons, David W.
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [35] Emerging gene therapies for cystic fibrosis
    Miah, Kamran M.
    Hyde, Stephen C.
    Gill, Deborah R.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (08) : 709 - 725
  • [36] Gene and cell therapy for cystic fibrosis: From bench to bedside
    Conese, Massimo
    Ascenzioni, Fiorentina
    Boyd, A. Christopher
    Coutelle, Charles
    De Fino, Ida
    de Smedt, Stefaan
    Rejman, Joanna
    Rosenecker, Joseph
    Schindelhauer, Dirk
    Scholte, Bob J.
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 : S114 - S128
  • [37] Gene Therapy with Adeno-associated Virus for Cystic Fibrosis
    Karda, Rajvinder
    Buckley, Suzanne M. K.
    Waddington, Simon N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193 (03) : 234 - 236
  • [38] SP-101, A Novel Adeno-Associated Virus Gene Therapy for the Treatment of Cystic Fibrosis, Mediates Functional Correction of Primary Human Airway Epithelia From Donors with Cystic Fibrosis
    Excoffon, Katherine J. D. A.
    Lin, Shen
    Narayan, Poornima Kotha Lakshmi
    Sitaraman, Sneha
    Jimah, Awal M.
    Fallon, Tyler T.
    James, Melane L.
    Glatfelter, Matthew R.
    Limberis, Maria P.
    Smith, Mark D.
    Guffanti, Guia
    Kolbeck, Roland
    HUMAN GENE THERAPY, 2024, 35 (17-18) : 695 - 709
  • [39] Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis
    Qinshi Jiang
    John F Engelhardt
    European Journal of Human Genetics, 1998, 6 : 12 - 31
  • [40] Gene Therapy for Cystic Fibrosis: Lessons Learned and Paths Forward
    Choi, Soon H.
    Engelhardt, John F.
    MOLECULAR THERAPY, 2021, 29 (02) : 428 - 430